New imaging tools put to the test for measuring dry eye treatment effects

NCT ID NCT07722624

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether two specialized eye imaging devices—the LipiView II and Keratograph 5M—can detect changes in tear film stability after using Miebo eye drops in people with dry eye. Twenty adults with normal tear film will have their eyes measured before and at several time points after a single dose of Miebo. The goal is to see if these devices can reliably track how the tear film responds to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Miebo (perfluorohexyloctane) eye drops
What this could lead to
If successful, this could improve how doctors diagnose and monitor dry eye disease by using advanced imaging to measure tear film stability.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to all dry eye patients. The imaging devices may not detect meaningful changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Butchertown Clinical Trials

    RECRUITING

    Louisville, Kentucky, 40206, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.